A systematic review and meta-analysis found a substantial burden of low bone mineral density among adults with chronic pancreatitis. Across 10 studies including 513 patients, the pooled prevalence of osteoporosis was 24.3%, while osteopenia affected 39.8%; overall, an estimated 65% had either condition. Pancreatic exocrine insufficiency (PEI) was associated with lower bone density in 5 of 9 studies that evaluated it, and lower body mass index also emerged as a potential risk factor, whereas associations with vitamin D levels, age, sex, and disease duration were inconsistent. A separate retrospective study cited in the review found fractures in 4.8% of patients with chronic pancreatitis vs 1.1% of controls.

The authors suggest incorporating bone-health assessment into the routine medical and nutritional evaluation of patients with chronic pancreatitis and propose that these patients receive DXA screening consideration similar to other gastrointestinal populations at increased osteoporosis risk. However, the evidence base was heterogeneous and generally small: only 4 of 11 included studies that were rated high quality, most lacked control groups, and the pooled osteoporosis analysis showed substantial heterogeneity. Although timely pancreatic enzyme replacement therapy (PERT) remains important for PEI, the review found no published evidence showing that PERT itself improves bone density. This underscores the need for better prospective studies and dedicated bone-health guidance for chronic pancreatitis.

Reference: Duggan SN, Smyth ND, Murphy A, et al. High prevalence of osteoporosis in patients with chronic pancreatitis: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2014 Feb;12(2):219-228. doi: 10.1016/j.cgh.2013.06.016. PMID: 23856359.

A review of animal and clinical studies suggests that pancreatic exocrine insufficiency (PEI) may contribute to gut microbial dysbiosis, including bacterial overgrowth, reduced microbial diversity, and shifts in specific bacterial populations. Pancreatic exocrine function appears to influence the intestinal microbiome through several mechanisms, including secretion of antimicrobial peptides and digestive enzymes, regulation of duodenal pH, bile acid handling, and the amount of undigested nutrients reaching the intestine. Clinical studies in chronic pancreatitis have similarly found lower microbial diversity and differences in bacterial composition among patients with PEI. However, the available human evidence remains limited and not entirely consistent.

Pancreatic enzyme replacement therapy (PERT) may partially reverse some of these microbiome changes. Animal studies found that PERT increased microbial diversity toward levels seen in healthy controls and altered the abundance of several bacterial groups, including increases in potentially beneficial species such as Akkermansia muciniphila. The relationship also may be bidirectional: changes in the gut microbiota and microbial metabolites may influence pancreatic exocrine function, suggesting a gut-pancreas feedback loop. The authors emphasize that more clinical research is needed to determine whether microbiome changes have meaningful diagnostic or therapeutic implications for patients with PEI.

Reference: Guo Y, Cao F, Li F. Impacts of pancreatic exocrine insufficiency on gut microbiota. J Zhejiang Univ Sci B. 2024 Apr 15;25(4):271-279. doi: 10.1631/jzus.B2300070. PMID: 38584090; PMCID: PMC11009442.

An editorial commentary argues that pancreatic exocrine insufficiency (PEI) management should move beyond symptom relief toward a treat-to-target approach focused on nutritional recovery. Current guidance supports identifying at-risk patients early, using fecal elastase-1 (FE-1) as a first-line test, and starting pancreatic enzyme replacement therapy (PERT) at adequate doses with structured titration. Yet, real-world gaps remain: FE-1 testing is inconsistent, PERT may be underdosed, and follow-up often emphasizes diarrhea or bloating rather than weight, micronutrients, muscle mass, and bone health. In an outpatient laboratory audit of 64 stool samples, 26.6% met the biochemical threshold for PEI and 15.6% met criteria for severe PEI. However, clinical information was unavailable to determine the underlying diagnoses or treatment status.

The authors propose a practical clinic pathway that includes baseline weight and nutritional assessment, prompt initiation of adequately dosed PERT, and reassessment after 4-8 weeks. If symptoms, weight trajectory, or nutritional markers have not improved, clinicians should consider dose escalation, optimize enzyme timing with meals, and evaluate potential confounders such as small intestinal bacterial overgrowth or bile acid diarrhea. Longer-term monitoring should include micronutrient status, sarcopenia, and bone health, with clinical and laboratory reassessment approximately every 6 months and DXA when appropriate. The central message is that improvement in gastrointestinal symptoms alone may not indicate adequate digestion. Treatment success also should include objective stabilization or improvement in nutritional status.

Reference: Lai Y, Wu D. Treat-to-target in pancreatic exocrine insufficiency: moving from symptom control to nutrition outcomes. HepatoBiliary Surg Nutr. 2026 Mar 25;15(2):55. doi: 10.21037/hbsn-2026-0177.